Proxy advisory firms Institutional Shareholder Service (ISS) and Glass Lewis & Co. (Glass Lewis) recently released their United States policy recommendations for...
December 19, 2017
Quebec is proposing to prohibit owner pharmacists from procuring generic medications from the same manufacturer in an amount in excess of 50% of the monetary value of all the generic medications purchased by that pharmacist during a given calendar year.
November 07, 2017
Thirteenth edition highlights ever-increasing threat to cyber security and data protection
October 25, 2017
Quebec intends to reimpose a 15% cap on the value of professional allowances that generic drug manufacturers are permitted to pay to pharmacists.
August 02, 2017
Given the complexity of modern healthcare systems, it is perhaps no surprise that the potential applications of blockchain technology which, to date, have been best publicised in the financial services sector, are only now becoming apparent in the life sciences and healthcare sectors.
May 19, 2017
The Canadian Senate has passed Bill C-30 (the act intended to implement CETA), the final major stage of the legislative process. Bill C-30 will become law once it receives royal assent, which we expect to happen shortly.
May 12, 2017
The Government of Canada has published draft regulations pursuant to Vanessa’s Law that provide details regarding the Minister of Health’s powers to require tests, assessments and studies of a drug post-market authorization and set out additional reporting requirements for manufacturers based on the actions of foreign regulators.
May 08, 2017
Major reforms to Canada’s Patent Act are coming soon, including the implementation of patent term restoration (i.e., Certificates of Supplementary Protection (CSP)), which may extend the patent term of eligible pharmaceutical products by up to two years.
May 04, 2017
Health Canada has proposed regulations that will amend the Food and Drug Regulations to allow for importation of drugs that address an urgent public health need but have not yet received regulatory approval from Health Canada
May 02, 2017
The Federal Court of Appeal dismissed BMS’s appeal from the Federal Court’s finding that claims for the bisulfate salt of atazanavir were obvious, and provided guidance on the meaning of “inventive concept” and the application of the leading Plavix decisions to obviousness.
April 25, 2017